Compare Howmet Aerospace Inc (HWM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs Merck & Co., Inc. — how do they compare? Howmet Aerospace Inc trades at $225.24 (market cap $88.76B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 4× Howmet Aerospace Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Merck & Co., Inc. for 98 Days on average.
| HWM | MRK | |
|---|---|---|
Market Cap | $88.76B | $351.28B |
Volume | 2,648,516 | 7,969,665 |
Sector | Industrials | Health |
52-Week High | $292.65 | $156.43 |
52-Week Low | $184.09 | $82.49 |
Typical Hold Time | 35 Days | 98 Days |
Enterprise Value | $92.86B | $398.04B |
Dividend Yield | 0.25% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $222.53, down 0.08% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, with revenue and earnings growth, a net income margin of 20.52%, and consistent quarterly EPS beats. Analyst consensus is overwhelmingly bullish with a $328.10 price target, supported by positive news on defense and aerospace demand.
The outlook for HWM is positive due to robust financial performance and sector tailwinds, but risks include technical weakness and competitive pressures. Investment opportunity lies in its growth trajectory and shareholder returns, though investors should monitor execution risks and market volatility.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
